Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 7 Days
Synthesis:
Over the past week, CMS finalized significant changes to Medicare Advantage (MA) and Part D payment policies for 2027, including a 2.48% average rate increase that substantially exceeds the initially proposed 0.09%, injecting approximately $13 billion in additional payments to MA organizations. The updates include finalized Part D risk adjustment changes that more clearly separate MA-PDs from PDPs and codify the ongoing Part D redesign—trends poised to recalibrate plan incentives, payment accuracy, and drug coverage, particularly for high-cost therapies tied to obesity and cardiometabolic disease as seen in the ongoing evolution of the BALANCE program. These changes intensify pressure on MA plans and downstream providers to optimize risk capture, adapt care models, and manage pharmacy benefits as CMS signals a greater focus on sustainability, selection risk, and quality accountability for value-based care stakeholders.
Related Articles
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Premier Responds to RFI on Potential 340B Rebate Model Pilot Program
Premier raised concerns that a rebate based approach to the 340B drug discount program would undermine the program and create significant risk for hospitals.
Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications
For millions of Americans, accessing the medications they need at prices they can afford has gotten increasingly difficult.
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come Health Affairs
Trump announces tariffs as high as 100% on pharmaceuticals
President Donald Trump has announced a new pharmaceutical tariff that would impose as much as 100% on imported brand-name drugs. The executive order, announced Thursday, is to spur the production of p...
In a first, a drugmaker’s lawsuit challenges HRSA’s 340B patient definition
In a new chapter for litigation involving the 340B Drug Pricing Program, a drugmaker is suing the federal government over the definition of patient as it pertains to the program. AbbVie Inc. says the ...
Recent 340B Court Rulings Sustain Blocked WV Law, Demand Decade-Old Federal Policy Be Set Aside
InsideHealthPolicy reports that a federal court ruled in favor of Premier Inc., vacating a decade-old HRSA policy limiting how certain 340B hospitals purchase drugs through group purchasing organizati...
Federal Court Vacates HRSA’s 2013 340B Guidance Prohibiting DSH GPO Use and Replenishment Models
Court vacates 340B policy on hospital drug purchasing: 6 things to know
Becker’s Hospital Review reports that a federal court ruled in favor of Premier Inc., vacating a 2013 HRSA policy restricting 340B hospital drug purchasing after finding the agency failed to adequatel...
Judge vacates HRSA's restriction on 340B hospital 'replenishment models'
Fierce Healthcare covers a federal court ruling vacating HRSA’s 2013 340B purchasing restriction following a lawsuit brought by Premier.